Osteologix, Inc. (OTC BB: OLGX), a specialty biopharmaceutical company, has dedicated their efforts to improving the health of those afflicted with musculoskeletal diseases through the development of innovative therapies. NB S101, the company’s lead investigational product candidate, is an innovative pharmaceutical agent designed to treat and prevent osteoporosis. Their mission is to partner with the healthcare community to apply new scientific information to the development of beneficial products. For more information please visit www.osteologix.com.
- 17 years ago
QualityStocks
Osteologix, Inc. (OTC BB: OLGX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…
-
QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Distinct Against Walker Lane Backdrop
Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is positioned as investors view the Walker Lane corridor in…
-
QualityStocksNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Targets $1 Billion AUM for Tokenized USD Money Market Product by Year-End 2025
Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced an initiative…